The CTC has a long standing interest in haematology trials. Historically the main focus was on lymphoma but over recent years the portfolio has expanded to include myeloma and leukaemia. The group has also developed an interest in transplant trials.

There are currently 14 trials open for recruitment and these include single arm phase II trials, a randomised phase II trial and phase III trials. Open trials are available for patients with a Hodgkin lymphoma, non-Hodgkin lymphoma (including a number of rare subtypes), myeloma and acute lymphoblastic leukaemia.

In the near future we will be opening trials for patients with AL amyloidosis and chronic lymphocytic leukaemia. Further details will be posted on this website when available.

Trials

Trial Name (Short)Trial NameStatusView
AITL Trial A Phase II Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma In follow-up Details
Bortezomib Consolidation Trial (BCT) PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA Recruiting Details
CHOP Campath A Pilot study of CHOP plus Campath for the primary treatment of ALK-ve peripheral T cell lymphoma In follow-up Details
FoRT Follicular Radiotherapy Trial - A Phase III multi-centre randomised controlled trial of low dose radiotherapy for follicular lymphoma and marginal zone lymphoma. In follow-up Details
GemBex A Phase II study of Gemcitabine and Bexarotene in the treatment of cutaneous T-cell lymphoma In follow-up Details
ITCL Trial A phase II evaluation of high dose chemotherapy and autologous stem cell transplantation for Intestinal and other subtypes of aggressive T-Cell Lymphoma. Recruiting Details
MAC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Myeloablative Conditioning Regimen Recruiting Details
MCL Mini Allo Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma. Recruiting Details
MELT - MRI Evaluation of Lymphoma Treatment Whole body functional and anatomical MRI: Accuracy in staging and treatment response monitoring in Adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging Recruiting Details
PADIMAC Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT. Recruiting Details
PAIReD Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma Recruiting Details
ProT4 Prophylactic Transfer of CD4 Lymphocytes Recruiting Details
RATHL A randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma In follow-up Details
R-CHOP 14vs21 A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma. Recruiting Details
R-CODOX-M/IVAC A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt’s Lymphoma (BL) of International Prognostic Index (IPI) High or High Intermediate Risk Recruiting Details
ReACH Phase II study of reduced intensity sibling allogeneic transplantation for relapsed, chemosensitive, PET positive Hodgkin lymphoma Recruiting Details
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning Regimen Recruiting Details
UKALL14 A randomised trial for adults with newly diagnosed acute lymphoblastic leukaemia Recruiting Details
UKALL60+ A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia Recruiting Details
Watch & Wait An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a) In follow-up Details